UPB Upstream Bio, Inc.
Healthcare · Market cap: $152.3M
–
Bought and sold by quarter, last 5 years
Open-market purchases and sales by this company's insiders, in dollars, last 5 years
| Quarter | Bought | Sold |
|---|---|---|
| 2022-Q1 | $0 | $0 |
| 2022-Q2 | $0 | $0 |
| 2022-Q3 | $0 | $0 |
| 2022-Q4 | $0 | $0 |
| 2023-Q1 | $0 | $0 |
| 2023-Q2 | $0 | $0 |
| 2023-Q3 | $0 | $0 |
| 2023-Q4 | $0 | $0 |
| 2024-Q1 | $0 | $0 |
| 2024-Q2 | $0 | $0 |
| 2024-Q3 | $0 | $0 |
| 2024-Q4 | $48.0M | $0 |
| 2025-Q1 | $0 | $0 |
| 2025-Q2 | $0 | $0 |
| 2025-Q3 | $0 | $0 |
| 2025-Q4 | $0 | $0 |
| 2026-Q1 | $0 | $46.6K |
| 2026-Q2 | $0 | $30.6K |
| 2026-Q3 | $0 | $27.6K |
| 2026-Q4 | $0 | $0 |
Bought$48.0M3 buy days
Sold$104.8K15 sell days
Net insider flow+$47.9Mnet buying · 5 years
Latest trade2026-09-16Sutherland Everett Rand
| Date | Side | Insider | Role | Shares | Avg price | Value | Trades |
|---|---|---|---|---|---|---|---|
| 2026-09-16 | Sell | Sutherland Everett Rand | CEO | 2,095 | $5.49 | $11.5K | 1 |
| 2026-09-16 | Sell | Deykin Aaron | Other C-suite | 895 | $5.49 | $4.9K | 1 |
| 2026-09-16 | Sell | GRAY MICHAEL | CFO | 853 | $5.49 | $4.7K | 1 |
| 2026-09-16 | Sell | Houghton Adam | Other C-suite | 700 | $5.49 | $3.8K | 1 |
| 2026-09-16 | Sell | Ambrose Allison | General counsel | 485 | $5.49 | $2.7K | 1 |
| 2026-06-16 | Sell | Sutherland Everett Rand | CEO | 2,095 | $6.10 | $12.8K | 1 |
| 2026-06-16 | Sell | Deykin Aaron | Other C-suite | 895 | $6.10 | $5.5K | 1 |
| 2026-06-16 | Sell | GRAY MICHAEL | CFO | 853 | $6.10 | $5.2K | 1 |
| 2026-06-16 | Sell | Houghton Adam | Other C-suite | 700 | $6.10 | $4.3K | 1 |
| 2026-06-16 | Sell | Ambrose Allison | General counsel | 477 | $6.10 | $2.9K | 1 |
| 2026-03-16 | Sell | Sutherland Everett Rand | CEO | 2,093 | $9.29 | $19.4K | 1 |
| 2026-03-16 | Sell | Deykin Aaron | Other C-suite | 894 | $9.29 | $8.3K | 1 |
| 2026-03-16 | Sell | GRAY MICHAEL | CFO | 852 | $9.29 | $7.9K | 1 |
| 2026-03-16 | Sell | Houghton Adam | Other C-suite | 699 | $9.29 | $6.5K | 1 |
| 2026-03-16 | Sell | Ambrose Allison | General counsel | 475 | $9.29 | $4.4K | 1 |
| 2024-10-15 | Buy | Blavatnik Len | 10% owner | 1,175,000 | $17.00 | $20.0M | 1 |
| 2024-10-15 | Buy | ORBIMED ADVISORS LLC | Director | 825,000 | $17.00 | $14.0M | 2 |
| 2024-10-15 | Buy | Chimovits Erez | Director | 825,000 | $17.00 | $14.0M | 2 |
Who the insiders are, last 5 years
Everyone who bought or sold this company's shares on the open market in the last 5 years, biggest first.
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Blavatnik Len | 10% owner | $20.0M | $0 | 2024-10-15 |
| Chimovits Erez | Director | $14.0M | $0 | 2024-10-15 |
| ORBIMED ADVISORS LLC | Director | $14.0M | $0 | 2024-10-15 |
| Sutherland Everett Rand | CEO | $0 | $43.7K | 2026-09-16 |
| Deykin Aaron | Other C-suite | $0 | $18.7K | 2026-09-16 |
| GRAY MICHAEL | CFO | $0 | $17.8K | 2026-09-16 |
| Houghton Adam | Other C-suite | $0 | $14.6K | 2026-09-16 |
| Ambrose Allison | General counsel | $0 | $10.0K | 2026-09-16 |
Past buying clusters
A cluster is a run of purchases by three or more insiders. Returns are the stock's return minus its benchmark's (IWM for small companies, SPY otherwise), from the first open after the run became a cluster. Past results, not a forecast.
| Window | Insiders | Total | Score | 21 days vs benchmark | 63 days vs benchmark | 126 days vs benchmark | Status |
|---|---|---|---|---|---|---|---|
| 2024-10-15 | 3 | $48.0M | 42 | -1.7% (-1.0% raw) | -59.3% (-55.1% raw) | -55.5% (-63.3% raw) | closed |
Yahoo Finance data, delayed, loaded through this server. Informational only; not investment advice.